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LETTER TO THE EDITOR
Pulmonary sarcoidosis in the Bronchoscopy  was  normal,  and  transbronchial  biopsy  showed
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hcontext of a telaprevir-based
triple therapy for hepatitis C
Dear  Editor,
We  would  like  to  present  the  ﬁrst  case  of  a  patient
coinfected  with  human  immunodeﬁciency  virus  (HIV)
and  hepatitis  C  virus  (HCV),  diagnosed  with  pulmonary
sarcoidosis  in  the  context  of  a  triple  therapy  with  pegylated-
interferon,  ribavirin  and  telaprevir.
A  50-year-old  man,  diagnosed  with  HIV  in  1993,  stage
A2,  treated  with  antiretroviral  therapy:  tenofovir,  emtric-
itabine  and  raltegravir.  In  2004  was  diagnosed  with  chronic
hepatitis  C,  genotype  1a  with  F2  degree  of  liver  ﬁbrosis,
and  treated  during  24  weeks  with  pegylated-interferon  and
ribavirin,  presenting  partial  response.
In  2013,  the  patient  was  treated  with  telaprevir-
based  triple  therapy  according  to  the  regimen:  telaprevir
2250  mg/day  for  the  ﬁrst  12  weeks;  pegylated-interferon
2a  180  mcg/week  and  ribavarin  1200/day  for  a  total  of  48-
weeks.  At  the  time  of  starting  treatment,  the  patient  had  a
F3  degree  of  ﬁbrosis  determined  by  Fibroscan® (9.9  kPa),  a
HCV  VL  of  5,810,000  IU/ml,  CT  IL28B  polymorphism,  a  CD4
count  of  544  cells/mm3 (32%),  HIV  VL  <20  copies/ml,  ALT  of
75  IU/L  and  AST  of  62  IU/L,  the  rest  of  the  analytical  was  nor-
mal.  During  the  following  weeks,  he  did  not  show  relevant
adverse  events.
At week  43,  the  patient  started  having  dyspnea  and
chest  pain  without  fever,  symptoms  that  worsened  in  the
following  weeks.  The  chest  radiography  showed  bilateral
diffuse  interstitial  lung  disease,  ground-glass  opacities  and
mediastinal  lymphadenopathy.  Also,  a  lung  scan  was  per-
formed  and  no  ﬁndings  of  acute  pulmonary  embolism  were
observed.  The  gas  analysis  showed:  pCO2:  31.2  mmHg,  pO2:
68.2  mmHg,  O2 saturation:  95.9%  and  pH:  7.47,  and  the  bio-
chemistry  showed  an  angiotensin-converting  enzyme  value
greater  than  100.
Two  weeks  later,  the  patient  presented  clinical  improve-
ment  (after  drug  treatment  with  antibiotics  and  bron-
chodilators)  but  with  persistent  injury  in  chest  radiography,
so  a  thoracic  CT  was  performed,  showing  bilateral
and  diffuse  ground-glass  opacities,  multiple  centrilobular
micronodules  (Fig.  1)  and  mediastinal  lymphadenopathy.
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nd  Groccott  staining  were  negative,  as  PCR  and  mycobac-
eria  culture.  After  completing  HCV  treatment,  the  clinical
ourse  of  the  patient  was  favorable,  showing  the  following
horacic  CT  gradual  improvement  in  lung  and  lymph  node
nvolvement,  and  ﬁnally,  a  year  later,  the  resolution  of  the
isease  (Fig.  2).
HCV  VL  values  became  undetectable  at  week  8  and
emained  undetectable  24  weeks  after  completion  of  HCV
herapy,  reaching  sustained  viral  response  (SVR).  In  addition,
he  liver  function  values  normalized  after  28  weeks  of  treat-
ent  (ALT  31  IU/L,  AST:  35  IU/L),  and  remained  within  the
ormal  range  24  weeks  after  completion  of  antiviral  therapy.
Sarcoidosis  is  a  granulomatous  disease  of  unknown  origin
nd  multisystemic  character,  in  which  lung,  liver,  lymphoid
ystem  and  skin  are  the  most  affected  organs.1 Although  its
tiology  is  unknown,  probably  an  exaggerated  response  to
arious  antigens  as  mycobacterias,  environmental  agents  or
utoantigens,  produces  an  abnormal  activation  of  CD4+  T
ells,  activating  peripheral  blood  monocytes,  and  causing
he  formation  of  granulomas.2
Diagnosis  of  sarcoidosis  is  often  a  matter  of  exclusion,
s  in  our  case;  there  is  no  speciﬁc  test  for  the  condition.
ll  the  ﬁndings  of  our  case  raised  the  possibility  of  a  dif-
erential  diagnosis  of  granulomatous  inﬂammation  caused
y  infection  or  sarcoidosis.  Findings  on  cultures  for  viral,
ungal  and  mycobacterial  organisms  were  negative.  Radio-
ogical  ﬁndings  and  clinical  manifestations  were  consistent
ith  an  atypical  pulmonary  sarcoidosis.  Similar  clinical  ﬁnd-
ngs  were  reported  in  other  cases  of  sarcoidosis  associated
ith  interferon.1,3,4
Interferon  is  a  cytokine  with  immunomodulatory  activ-
ty  on  T  lymphocytes,  which  is  successfully  used  in  the
reatment  of  hepatitis  C.  Several  adverse  effects  have
een  described  for  interferon  therapies,  like  hemato-
ogic  symptoms,  ﬂu-like  symptoms,  and  cutaneous  events,5
nd  although  the  exact  mechanism  of  action  is  unknown,
nterferon  is  also  associated  with  the  occurrence  of
ertain  immunological  diseases  like  hemolytic  anemia,
ypothyroidism,  and  sarcoidosis.3,5 The  majority  of  patients
chieved  spontaneous  resolution  of  sarcoidosis  after  stop-
ing  treatment  with  interferon,  and  there  is  also  evidence
f  remission  in  spite  of  continuing  treatment,  demonstrating
hat  interferon  may  play  a  role  in  its  appearance,  but  not
lsevier España, S.L.U. All rights reserved.
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Figure  1  Sarcoidosis  in  50  years-old  man,  coinfected  with  HIV  and  HCV,  and  treated  with  telaprevir-based  triple  therapy.  Thin-
section of  thoracic  CT  shows  bilateral  and  diffuse  ground-glass  opacities,  and  multiple  centrilobular  micronodules.
Figure  2  Sarcoidosis  in  50  years-old  man,  coinfected  with  HIV  and  HCV,  and  treated  with  telaprevir-based  triple  therapy.  Thin-
section of  thoracic  CT  shows  sarcoidosis  resolved  a  year  after  stopping  HCV  treatment.  Small  calciﬁed  micronodules  are  observed.
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Rn  the  maintenance,  so  the  decision  to  continue  treatment
hould  be  assessed  depending  on  the  risk-beneﬁt  balance.
n  our  case,  the  patient  continued  the  treatment  until  com-
letion,  reaching  SVR,  and  showing  clinical  and  radiological
mprovement  since  the  end  of  treatment.
The  systemic  manifestations  of  sarcoidosis  are  usually
reated  with  oral  steroids,  but  it  often  increases  the  hep-
titis  C  viral  load.  In  this  case,  it  was  not  necessary  to  use
orticosteroid  treatment,  and  sarcoidosis  was  resolved  after
topping  HCV  treatment,  which  may  indicate  the  role  of  HCV
reatment  in  his  appearance.
Although  there  are  several  articles  about  the  relationship
etween  sarcoidosis  and  interferon,  their  relationship  with
ibavirin  cannot  be  ruled,  because  it  can  activate  the  Th1
elper  lymphocytes,  or  even  with  telaprevir,  this  occurred  in
nother  case  of  sarcoidosis  in  a  patient  treated  with  telapre-
ir,  ribavirin  and  standard  interferon  3  times  per  week.4
1
2This  case  draws  attention  to  this  serious  side  effect  that
ome  patients  may  experience  during  the  antiviral  treat-
ent,  and  it  is  essential  that  the  diagnosis  of  sarcoidosis
s  considered  in  patients  with  compatible  clinical  ﬁndings.
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Response to imatinib in patient
with corticosteroid-
unresponsive idiopatic
hypereosinophilic syndrome
Dear  Editor,
Hypereosinophilia  (HE)  is  deﬁned  as  peripheral  blood
eosinophils  >1.5  eosinophils  ×  109/L  blood  on  2  examinations
and/or  tissue  HE  deﬁned  by  the  following:  (1)  the  percent-
age  of  eosinophils  in  the  bone  marrow  section  exceeds  20%
of  all  nucleated  cells  and/or  (2)  the  pathologist  is  of  the
opinion  that  tissue  inﬁltration  by  eosinophils  is  extensive
and/or  (3)  marked  deposition  of  eosinophil  granule  proteins
is  found  (in  the  absence  or  presence  of  major  tissue  inﬁl-
tration  by  eosinophils).  Hypereosinophilic  syndrome  (HES)
is  deﬁned  by  the  following:  (1)  criteria  for  peripheral  blood
hypereosiniphilia  (HE)  fulﬁlled  and  (2)  organ  damage  and/or
dysfunction  attributable  to  tissue  HE  and  (3)  exclusion  of
other  disorders  or  conditions  as  major  reason  for  organ  dam-
age.  HES  subtypes  have  been  deﬁned;  these  include  (1)
idiopathic  HES,  (2)  primary  (neoplastic)  HES,  (3)  secondary
(reactive)  HES.1 We  here  report  a  case  of  idiopathic  hyper-
eosinophilic  syndrome  successfully  treated  with  imatinib.
A  forty-six-year-old  male  patient  was  admitted  to  our
clinic  with  complaints  of  itching,  cough,  shortness  of  breath,
and  stomach  pain.  The  symptoms  had  increased  over  the
last  six  months.  He  had  a  history  of  chronic  smoking
(30  pack-years).  There  was  no  history  of  any  drug  use.
Admission  blood  pressure:  110/80  mmHg;  respiratory  rate
20/min;  pulse  95/min;  saturation  in  room  air  was  found  to
be  95%.  Breath  sounds  were  bilaterally  decreased.  Widely
excoriated  itchy  lesions  were  present.  There  was  tender-
ness  in  the  epigastric  region.  Blood  eosinophil  rate  was
55.4%  (9880/mm3).  Parasite  stool  examination  and  sero-
logic  tests  were  negative.  A  mild  obstructive  pattern  was
present  in  the  pulmonary  function  test.  However,  the
patient  did  not  beneﬁt  from  treatment  with  high  doses
of  inhaled  corticosteroids/2  agonists.  Laboratory  tests
showed  no  signiﬁcant  alterations  except  increased  vitamin
Centrilobular  ground-glass  nodules  were  found  to  be
more  prominent  in  the  upper  lobes  of  the  lungs  in
thorax  computed  tomography  (CT)  (Fig.  1a).  Abdomi-
nal  CT  and  ultrasonography  were  found  to  be  normal.
Endoscopic  biopsy  for  stomach  pain  was  reported  as
eosinophilic  gastritis.  Eosinophilic  inﬁltration  was  observed
on  transbronchial  lung  biopsy.  Numerous  eosinophilic  gran-
ulocytes  (40%)  were  observed  in  bone  marrow  biopsy
without  increased  blast  cells.  A  prominent  mast  cell
population  was  not  observed.  There  was  no  malignant
inﬁltration.  FIPLI-PDGFR mutation,  JAK-2  mutation  and
Philadelphia  chromosome  were  also  found  to  be  nega-
tive.
In  our  case,  differential  diagnosis  was  performed  for  pri-
mary  (hematopoietic  neoplasms  with  HE)  and  secondary
HES,  (helminth  infections,  allergic  reactions,  atopic  dis-
eases,  drug  reactions  (allergic  or  toxic),  Hodgkin  disease,  B-
or  T-cell  lymphoma/leukemia,  Langerhans  cell  histiocytosis,
indolent  systemic  mastocytosis,  solid  tumors/malignancy,
allergic  bronchopulmonary  aspergillosis,  chronic  inﬂam-
matory  disorders,  autoimmune  diseases  and  lymphoid
variant  of  HES),  organ-restricted  conditions  accompanied
by  HE  (eosinophilic  gastrointestinal  disorders,  eosinophilic
pneumonia,  dermatologic  diseases,  etc.)  and  speciﬁc
syndromes  accompanied  by  HE  (Gleich  syndrome,  Churg-
Strauss  syndrome,  eosinophilia  myalgia  syndrome,  Hyper-IgE
syndrome).1--6 The  patient  was  diagnosed  with  idiopatic  HES
after  exclusion  of  all  primary  and  secondary  causes  and
exclusion  of  other  conditions  and  syndromes.  The  patient
was  started  on  imatinib  mesylate  therapy  with  400  mg/day
because  he  did  not  respond  to  corticosteroids  (CS)  and
hydroxyurea  therapy.  The  treatment  was  reduced  to  a
100  mg  in  the  third  month  of  treatment  due  to  normalization
of  eosinophil  levels  and  disappearance  of  all  complaints.  The
ground-glass  nodules  disappeared  after  1  year  of  imatinib
treatment  (Fig.  1b).
CS  have  been  used  for  decades  in  the  treatment  of  HES,
with  the  exception  of  PDGFR-  associated  HES.  A  number
of  cytotoxic  therapies  have  been  used  for  the  management
of  corticosteroid-refractory  HES.  Of  these,  hydroxyurea  has
been  the  most  extensively  studied.  However,  the  utility  ofB12:  1081  pg/ml  (reference  range:  111--663  pg/ml)  and  total
IgE:  194  IU/ml  (reference  range:  <100  IU/ml)  autoimmunity
work-up  was  negative.  Troponin  T  and  echocardiography
were  normal.
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tydroxyurea  monotherapy  is  limited  in  the  treatment  of
ES.  Imatinib  mesylate  is  a tyrosine  kinase  inhibitor  with
ctivity  against  several  receptor  tyrosine  kinases,  including
he  fusion  kinase  FIP1L1/PDGFR-,  which  is  responsi-
